secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001104659-25-005648
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS announces positive interim analysis for Phase 3 REGAL trial of GPS in AML; IDMC recommends continuation
--------------------------------------------------------------------------------

- IDMC recommended continuation of Phase 3 REGAL trial after interim analysis triggered by 60 deaths; no safety concerns.
- Blinded data: fewer than 50% of patients deceased after median follow-up of 13.5 months; pooled median survival >13.5 months vs ~6 months historical.
- Blinded immune response: 80% of GPS patients showed GPS-specific T-cell response, exceeding prior Phase 2 result of 64%.
- Next final analysis planned at 80 events, expected in 2025; company preparing BLA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/0001104659-25-005648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/tm254291d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-005648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer